Mays Cancer Center has large presence at ASCO Annual Meeting

Investigators from the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer, are presenting multiple research abstracts at this week’s Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Topics and links to abstracts are below. Congratulations to all Mays Cancer Center researchers for this fine work.

Impact of equal access by race and ethnicity on patients in the Veterans Health Administration (VHA) treated for diffuse large B-cell lymphoma (DLBCL).

(Presenter: Snegha Ananth, MD)

A two statewide population-based study evaluating ethnic patterns, differences in treatment and survival between Hispanics and non-Hispanics with peripheral T cell lymphoma.

(Presenter: Daniel Rosas, MD)

Race/ethnicity and outcomes in hematopoietic stem cell transplantation (HCT) in myeloproliferative neoplasms (MPN): A single institutional study.

(Presenter: Snegha Ananth, MD)

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.

(Presenter: Ruben A. Mesa, MD, FACP)

Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.

(Presenter: Munaf Alkadimi, MD)

An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19).

(Presenter: Dimpy P. Shah, MD, PhD)

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

(Presenter: Virginia G. Kaklamani, MD)

Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities.

(Authors include: Zohra Nooruddin, MD)

Discovering disparities in diffuse large B-cell lymphoma (DLBCL): A hispanic population comparison between Florida and Texas.

(Authors include: Adolfo Enrique Diaz Duque, MD)

Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy.

(Authors include Sukeshi Arora, MD)

Impact of imbalanced gender participation in online myeloproliferative neoplasm symptom surveys.

(Authors include Robyn Scherber, MD)

Does ethnicity matter? A two-statewide population based analysis of outcomes of primary mediastinal B-cell lymphoma in Hispanics.

(Presenter: Munaf Alkadimi, MD)

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).

(Authors include Ruben Mesa, MD, FACP)

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

(Authors include Virginia Kaklamani, MD)

Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].

(Authors include Ruben Mesa, MD, FACP)

Share This Article!